Scotiabank Lowers Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $442.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective cut by Scotiabank from $450.00 to $442.00 in a report published on Tuesday morning, Marketbeat reports. They currently have a sector perform rating on the pharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. boosted their target […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective cut by Scotiabank from $450.00 to $442.00 in a report published on Tuesday morning, Marketbeat reports. They currently have a sector perform rating on the pharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. boosted their target […]
